BPC 157 prevented and reversed life-threatening heart arrhythmias from bupivacaine overdose in rats across an extremely wide dose range, even after cardiac rhythm disturbances had already begun.
10 pg/kg to 50 µg/kgBPC 157 counteracted fatal bupivacaine cardiotoxicity across a million-fold dose range — an unusually wide therapeutic window
What the researchers found
BPC 157 prevented and counteracted bupivacaine cardiotoxicity in rats across an extremely wide dose range (10 pg/kg to 50 µg/kg). Given 30 minutes before or 1 minute after bupivacaine (100 mg/kg), it largely counteracted bradycardia, AV-block, ventricular arrhythmias, T-wave elevation, and asystole. Even when given 6 minutes after bupivacaine (after prolonged QRS had developed), it markedly postponed fatal outcomes. In vitro, BPC 157 (1 µM) inhibited bupivacaine-induced cell membrane depolarization in HEK293 cells.
Why it matters
Accidental bupivacaine overdose during local anesthesia can cause fatal heart arrhythmias, and current rescue options are limited. BPC 157’s ability to counteract cardiotoxicity across a million-fold dose range and even after arrhythmias have begun suggests a potential emergency antidote. The lack of known BPC 157 toxicity adds to its appeal as a rescue agent.
The numbers in context
Bupivacaine 100 mg/kg · BPC 157: 50 µg/kg to 10 pg/kg effective · pre-treatment (30 min) and post-treatment (1 min, 6 min) · QRS prolongation ≥20 ms threshold · 1 µM inhibited depolarization in vitro
How the study worked
Wistar rats received toxic-dose bupivacaine (100 mg/kg IP). BPC 157 was administered at four dose levels either 30 min before, 1 min after, or 6 min after bupivacaine. ECG monitoring assessed cardiac rhythm disturbances (bradycardia, AV-block, ventricular arrhythmias, QRS prolongation, T-wave elevation, asystole). In vitro, membrane voltage (Vm) was measured in HEK293 cells exposed to bupivacaine (1 mM) ± BPC 157 (1 µM).
Who was studied
Wistar rats with bupivacaine-induced cardiotoxicity and HEK293 cells in vitro
What this study cannot tell us
Rat model only — human cardiac physiology differs, and bupivacaine toxicity patterns may not be identical. The mechanism of cardioprotection is not fully elucidated. No human safety or efficacy data for this application. The extreme dose range (pg to µg) is unusual and the mechanism driving activity across such a range is unclear. All research comes from a single research group (Sikiric lab).
How to read the evidence
This is a preclinical study with both in vivo (rat) and in vitro (HEK293 cell) components. While the results are dramatic, all BPC 157 cardiotoxicity research comes primarily from a single research group, and independent replication is needed. No human data exists for this application.
When this study was published
Published in 2016, this is part of a long series of BPC 157 studies from the Sikiric group in Zagreb. While interest in BPC 157 has grown significantly, clinical trials for specific indications remain limited.
The bigger picture
BPC 157 continues to attract research interest for its remarkably broad cytoprotective effects. While most BPC 157 research comes from preclinical settings and a single research group, the finding of cardioprotection against anesthetic toxicity adds to a growing body of evidence suggesting this peptide has unusual and wide-ranging protective properties. If validated independently, it could address an unmet need in anesthesia safety.
Questions still open
- What is the molecular mechanism by which BPC 157 counteracts bupivacaine’s sodium channel blockade and membrane depolarization?
- Can these findings be replicated by independent research groups outside the Sikiric laboratory?
- Would BPC 157 show similar cardioprotective effects against other local anesthetic toxicities (lidocaine, ropivacaine)?
Common questions
What is BPC 157 and where does it come from?
Why is bupivacaine toxicity so dangerous?
Read the original research
Stable gastric pentadecapeptide BPC 157 and bupivacaine.
European journal of pharmacology, 793, 56-65
Citation
Zivanovic-Posilovic, Gordana; Balenovic, Diana; Barisic, Ivan; Strinic, Dean; Stambolija, Vasilije; Udovicic, Mario; Uzun, Sandra; Drmic, Domagoj; Vlainic, Josipa; Bencic, Martina Lovric; Sindic, Aleksandra; Seiwerth, Sven; Sikiric, Predrag. (2016). Stable gastric pentadecapeptide BPC 157 and bupivacaine.. European journal of pharmacology, 793, 56-65. https://doi.org/10.1016/j.ejphar.2016.10.035